137 related articles for article (PubMed ID: 17068112)
1. Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models.
Levites Y; Smithson LA; Price RW; Dakin RS; Yuan B; Sierks MR; Kim J; McGowan E; Reed DK; Rosenberry TL; Das P; Golde TE
FASEB J; 2006 Dec; 20(14):2576-8. PubMed ID: 17068112
[TBL] [Abstract][Full Text] [Related]
2. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease.
Asami-Odaka A; Obayashi-Adachi Y; Matsumoto Y; Takahashi H; Fukumoto H; Horiguchi T; Suzuki N; Shoji M
Neurodegener Dis; 2005; 2(1):36-43. PubMed ID: 16909001
[TBL] [Abstract][Full Text] [Related]
3. Peripheral and central biodistribution of (111)In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease.
Bacher M; Depboylu C; Du Y; Noelker C; Oertel WH; Behr T; Henriksen G; Behe M; Dodel R
Neurosci Lett; 2009 Jan; 449(3):240-5. PubMed ID: 18786612
[TBL] [Abstract][Full Text] [Related]
4. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model.
Dodart JC; Bales KR; Gannon KS; Greene SJ; DeMattos RB; Mathis C; DeLong CA; Wu S; Wu X; Holtzman DM; Paul SM
Nat Neurosci; 2002 May; 5(5):452-7. PubMed ID: 11941374
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
Geylis V; Steinitz M
Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
[TBL] [Abstract][Full Text] [Related]
6. Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies.
Hallé M; Tribout-Jover P; Lanteigne AM; Boulais J; St-Jean JR; Jodoin R; Girouard MP; Constantin F; Migneault A; Renaud F; Didierlaurent AM; Mallett CP; Burkhart D; Pilorget A; Palmantier R; Larocque D
J Immunol Methods; 2015 Sep; 424():64-79. PubMed ID: 26002154
[TBL] [Abstract][Full Text] [Related]
7. Intramuscular delivery of a single chain antibody gene prevents brain Aβ deposition and cognitive impairment in a mouse model of Alzheimer's disease.
Wang YJ; Gao CY; Yang M; Liu XH; Sun Y; Pollard A; Dong XY; Wu XB; Zhong JH; Zhou HD; Zhou XF
Brain Behav Immun; 2010 Nov; 24(8):1281-93. PubMed ID: 20595065
[TBL] [Abstract][Full Text] [Related]
8. Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
Levites Y; Das P; Price RW; Rochette MJ; Kostura LA; McGowan EM; Murphy MP; Golde TE
J Clin Invest; 2006 Jan; 116(1):193-201. PubMed ID: 16341263
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
Rakover I; Arbel M; Solomon B
Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
[TBL] [Abstract][Full Text] [Related]
10. Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice.
Luo F; Rustay NR; Seifert T; Roesner B; Hradil V; Hillen H; Ebert U; Severin JM; Cox BF; Llano DA; Day M; Fox GB
J Pharmacol Exp Ther; 2010 Dec; 335(3):580-8. PubMed ID: 20823195
[TBL] [Abstract][Full Text] [Related]
11. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
Chauhan NB; Siegel GJ
Expert Rev Vaccines; 2004 Dec; 3(6):717-25. PubMed ID: 15606357
[TBL] [Abstract][Full Text] [Related]
12. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease.
Lord A; Gumucio A; Englund H; Sehlin D; Sundquist VS; Söderberg L; Möller C; Gellerfors P; Lannfelt L; Pettersson FE; Nilsson LN
Neurobiol Dis; 2009 Dec; 36(3):425-34. PubMed ID: 19703562
[TBL] [Abstract][Full Text] [Related]
13. Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Abeta quantification following passive immunization with Abeta antibodies.
Lanz TA; Schachter JB
J Neurosci Methods; 2008 Mar; 169(1):16-22. PubMed ID: 18160105
[TBL] [Abstract][Full Text] [Related]
14. Novel approaches for immunotherapeutic intervention in Alzheimer's disease.
Vasilevko V; Cribbs DH
Neurochem Int; 2006 Jul; 49(2):113-26. PubMed ID: 16765487
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
Panza F; Frisardi V; Imbimbo BP; Seripa D; Solfrizzi V; Pilotto A
Expert Opin Biol Ther; 2011 Jun; 11(6):679-86. PubMed ID: 21501112
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of A beta plaque clearance following passive A beta immunization.
Morgan D
Neurodegener Dis; 2005; 2(5):261-6. PubMed ID: 16909007
[TBL] [Abstract][Full Text] [Related]
17. Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization.
Chang WP; Downs D; Huang XP; Da H; Fung KM; Tang J
FASEB J; 2007 Oct; 21(12):3184-96. PubMed ID: 17494994
[TBL] [Abstract][Full Text] [Related]
18. Rapid cerebral amyloid binding by Aβ antibodies infused into β-amyloid precursor protein transgenic mice.
Winkler DT; Abramowski D; Danner S; Zurini M; Paganetti P; Tolnay M; Staufenbiel M
Biol Psychiatry; 2010 Nov; 68(10):971-4. PubMed ID: 20359696
[TBL] [Abstract][Full Text] [Related]
19. Effect of rice-expressed amyloid β in the Tg2576 Alzheimer's disease transgenic mouse model.
Nojima J; Maeda A; Aoki S; Suo S; Yanagihara D; Watanabe Y; Yoshida T; Ishiura S
Vaccine; 2011 Aug; 29(37):6252-8. PubMed ID: 21726591
[TBL] [Abstract][Full Text] [Related]
20. Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576.
Chauhan NB; Siegel GJ
J Neurosci Res; 2003 Oct; 74(1):142-7. PubMed ID: 13130516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
